With the majority of EU countries opening their borders to non-essential travel, most have decided to maintain vaccination requirements in order to protect public health and avoid any potential resurgence of new COVID-19 infections.
However, since each EU member state has the right to decide on its own entry requirements, the travel process has been confusing for travelers for some time now that a large percentage of EU countries only recognize vaccines for travel that have been approved for use before European Medicines Agency (EMA).
However, shortly after the World Health Organization (WHO) announced that Covaxin had been officially approved for use, 12 countries in the European Union automatically accepted the vaccine as valid proof of travel immunity, TheSchengen.com reports.
Based on data provided by VisaGuide.World’s Vaccine Screening Tool, which enables travelers to validate their vaccine, all EU/Schengen area countries listed below now recognize Covaxin as valid proof of immunity to COVID-19:
Austria Estonia Finland Greece Hungary Iceland Latvia Netherlands Spain Slovakia Sweden Switzerland
Switzerland was one of the first countries to recognize Covaxin.
All the authorities of the above-mentioned countries announced their acceptance of all vaccination certificates that indicate that their holder has been immunized with one of the vaccines approved by the World Health Organization.
This means that once Covaxin received the green light from the World Health Organization, the vaccine was automatically accepted in these countries.
The statement “A person who has received a full course of vaccination with any vaccine registered by the European Medicines Agency or an equivalent vaccine registered by a regulatory body or recognized by the World Health Organization and has passed 14 days since the end of the course of vaccination” from the Latvian authorities reads.
In line with the majority of EU requirements, a vaccination document indicating that a holder of the vaccine has been immunized with Covaxin must include basic information about the holder, including name, surname, date of birth and dates of dosing, as well as the issuing authority.
According to a press release from the World Health Organization, the evaluation of Covaxin was based on a review of data on safety, quality, efficacy, risk management, and program appropriateness.
The vaccine is exceptionally suitable for low- and middle-income countries due to simple storage requirements and is recommended in two doses for all persons over 18 years of age.
Apart from the above countries now allowing entry to all who have been vaccinated with Covaxin, the Maltese authorities recently announced that travelers who have had WHO approved vaccines followed by an acceptable EMA booster dose will be allowed into the country.
This means that all travelers who have been vaccinated with Covaxin can now travel to Malta without being subject to additional entry rules provided they have taken a booster dose of one of the EMA approved vaccines.